RZLT — Rezolute, Inc. stock price, charts and financials

Latest market price

4.91

+0.19+4.03%

Overview Short InterestFilings

RZLTQT78Rezolute, Inc.·NASDAQ

Overview Short InterestFilings

4.91+4.03%

Loading chart...

Signal & projected range

Short-squeeze setupHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

IOVA+6.14%$4.32 FTRE-1.20%$18.94 SLS+12.09%$11.22 URGN+0.92%$38.59 MESO+2.12%$14.47 TSHA-1.37%$5.78 TYRA+0.50%$32.04 AUPH-2.08%$14.57

Snapshot

Index	-	P/E	-	EPS (ttm)	-	Insider Own	-	Shs Outstand	96.29M	Perf Week	-5.41%

Market Cap	454.50M	Forward P/E	-	EPS next Y	-0.33	Insider Trans	0.00%	Shs Float	66.01M	Perf Month	-4.65%

Enterprise Value	444.37M	PEG	-	EPS next Q	-0.13	Inst Own	-	Short Float	24.71%	Perf Quarter	47.50%

Income	-75.40M	P/S	0.00	EPS this Y	-	Inst Trans	-	Short Ratio	8.79	Perf Half Y	45.23%

Sales	0.00	P/B	4.20	EPS next Y	49.71%	ROA	-64.95%	Short Interest	16.31M	Perf YTD	100.00%

Book/sh	-	P/C	-	EPS next 5Y	-	ROE	-58.82%	52W High	11.92 -58.81%	Perf Year	-21.46%

Cash/sh	-	P/FCF	-	EPS past 3/5Y	-	ROIC	-73.68%	52W Low	1.11 341.12%	Perf 3Y	155.14%

Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-	Gross Margin	0.00%	Volatility	6.06% 6.71%	Perf 5Y	-53.54%

Dividend TTM	-	EV/Sales	0.00	EPS Y/Y TTM	30.08%	Oper. Margin	0.00%	ATR (14)	0.34	Perf 10Y	-90.56%

Dividend Ex-Date	-	Quick Ratio	15.84	Sales Y/Y TTM	-	Profit Margin	0.00%	RSI (14)	49.04	Recom	2.00

Dividend Gr. 3/5Y	-	Current Ratio	15.84	EPS Q/Q	0.00%	SMA20	-2.71%	Beta	0.54	Target Price	8.67

Payout	0.00%	Debt/Eq	0.01	Sales Q/Q	-	SMA50	5.06%	Rel Volume	0.43	Prev Close	4.72

Employees	71	LT Debt/Eq	0.01	Earnings	Sep 16	SMA200	0.13%	Avg Volume	1.80M	Price	4.91

IPO Date	Jan 14, 2013	Option/Short	Yes / Yes	EPS/Sales Surpr.	-17.79% -	Net Debt/EBITDA	0.12	Volume	776,968	Change	4.03%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Jun-03-26	Upgrade	Citizens	Market Perform → Market Outperform
Jun-03-26	Reiterated	Wedbush	Outperform	$2.00 → $6.00
Jun-02-26	Reiterated	BTIG	Buy	$5.00 → $6.00
May-14-26	Reiterated	Maxim Group	Buy	$4.00 → $10
Mar-25-26	Upgrade	Wedbush	Neutral → Outperform
Jan-08-26	Reiterated	Wedbush	Neutral	$1.00 → $2.00
Dec-12-25	Reiterated	Maxim Group	Buy	$4.00
Dec-12-25	Reiterated	HC Wainwright & Co.	Buy	$14 → $5.00
Dec-11-25	Reiterated	Craig-Hallum		$14 → $2.00
Dec-11-25	Reiterated	BTIG	Buy	$17 → $5.00

Latest News

Jul-21-26

Jul-21-2607:30AM

Rezolute to Participate in the BTIG Virtual Biotechnology Conferenceglobenewswire.com

Jun-17-26

Jun-17-2607:15AM

Rezolute Highlights ENDO Data On Congenital HI Outcomes And Tumor HI Case Series Supporting Ersodetug ProgramBenzinga

Jun-15-26

Jun-15-2611:12AM

Guggenheim Maintains Buy on Rezolute, Raises Price Target to $11Benzinga

Company

Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for the treatment of hypoglycemia; and clinical trials of ersodetug for tumor hyperinsulinism. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was founded in 2010 and is headquartered in Redwood City, California.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	FY 2025 6/30/2025	FY 2024 6/30/2024	FY 2023 6/30/2023	FY 2022 6/30/2022	FY 2021 6/30/2021	FY 2020 6/30/2020	FY 2019 6/30/2019	FY 2018 6/30/2018	FY 2017 6/30/2017
Total Revenue	0	0	0	0	0	0	0	0	0
Cost of Goods Sold Incl. D&A	0	0	0	0	0	0	0	1	13
Gross Profit	0	0	0	0	0	0	0	-1	-13
Selling, General and Administrative Excl. Other	18	15	12	9	8	6	7	9	8
Research and Development	62	56	44	32	15	14	19	17	12
Other Operating Expense	0	-1	0	1	0	1	0	0	0
Operating Income	-80	-70	-56	-42	-23	-21	-26	-29	-20
Interest Expense	0	0	0	2	0	0	5	1	0
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	5	2	4	3	2	0	0	0	0
Net Income Before Taxes	-74	-68	-52	-41	-21	-20	-30	-30	-20
Income Taxes	0	0	0	0	0	0	0	0	0
Consolidated Net Income	-74	-68	-52	-41	-21	-20	-30	-30	-20
Net Income From Continuing Operations	-74	-68	-52	-41	-21	-20	-30	-30	-20
Net Income	-74	-68	-52	-41	-21	-20	-30	-30	-20
EPS (Recurring)	-0.98	-1.33	-1.01	-2.26	-2.72	-3.54	-17.11	-26.83	-24.55
EPS (Basic, Before Extraordinaries)	-0.98	-1.33	-1.01	-2.26	-2.72	-3.54	-17.11	-26.83	-24.55
EPS (Diluted)	-0.98	-1.33	-1.01	-2.32	-2.72	-3.54	-17.11	-26.83	-24.55
EBITDA	-74	-68	-52	-39	-21	-20	-25	-28	-19
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	—	—	—	—	—	—	—	—	—
Price To Sales Ratio	—	—	—	—	—	—	—	—	—
Gross Margin	—	—	—	—	—	—	—	—	—
Operating Margin	—	—	—	—	—	—	—	—	—
Net Margin	—	—	—	—	—	—	—	—	—
Shares Outstanding	76	51	51	18	8	6	2	1	1
Market Capitalization	339	219	101	58	114	28	20	23	57
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Evans Daron	CFO	Mar 30 '26	Buy	2.85	10,000	28,500	414,462	Mar 31
Hogenhuis Wladimir	Director	Dec 16 '25	Buy	1.69	5,650	9,549	119,675	Dec 17
ROBERTS BRIAN KENNETH	Chief Medical Officer	Dec 16 '25	Buy	1.70	28,000	47,600	308,352	Dec 17
Evans Daron	CFO	Dec 15 '25	Buy	1.77	45,000	79,578	415,900	Dec 15
Elam Nevan C	CEO	Dec 15 '25	Buy	1.59	32,000	50,880	641,119	Dec 15
Karnawat Sunil Ratilal	Chief Commercial Officer	Dec 15 '25	Buy	1.62	12,100	19,599	71,542	Dec 15
ROBERTS BRIAN KENNETH	Chief Medical Officer	Jun 25 '25	Buy	4.38	2,500	10,939	15,500	Jun 26
Evans Daron	CFO	Jun 24 '25	Buy	4.05	5,000	20,250	268,900	Jun 24
Kim Young-Jin	Director	Jun 13 '25	Buy	3.25	1,230,769	3,999,999	8,423,386	Jun 23
KREHER NERISSA	Director	Jun 13 '25	Buy	3.25	3,076	9,997	37,576	Jun 23
Hogenhuis Wladimir	Director	Mar 31 '25	Buy	2.92	6,758	19,733	84,025	Apr 01
Elam Nevan C	CEO	Mar 27 '25	Buy	2.85	12,302	34,999	224,119	Mar 31
Evans Daron	CFO	Mar 26 '25	Buy	2.88	20,000	57,700	237,900	Mar 28
Hogenhuis Wladimir	Director	Feb 18 '25	Buy	4.70	10,000	47,000	77,267	Feb 20
Kim Young-Jin	Director	Jun 25 '24	Buy	4.00	1,250,000	5,000,000	7,192,617	Feb 19

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.